SCHEDULE: Vanguard Amends Emergent BioSolutions Stake

The Vanguard Group filed an amended Schedule 13G, disclosing its beneficial ownership of 6.76% of Emergent BioSolutions Inc. common stock.

Summary

• The Vanguard Group reported beneficial ownership of 3,553,999 shares of Emergent BioSolutions Inc. common stock.
• This represents 6.76% of the class of securities.
• The filing is an Amendment No. 14 to a Schedule 13G.
• The Vanguard Group holds shared voting power over 356,748 shares and shared dispositive power over 3,553,999 shares.
• An internal realignment at The Vanguard Group, Inc. occurred on January 12, 2026, where it no longer performs portfolio management services or administers proxy voting.
• Certain subsidiaries or business divisions of The Vanguard Group, Inc. are expected to report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of beneficial ownership and an internal organizational change at the reporting entity, with no direct positive or negative implications for the issuer's operational performance.

Positives

• The Vanguard Group, a major institutional investor, maintains a significant stake in Emergent BioSolutions Inc., indicating continued investment interest.

Future Outlook

Following an internal realignment on January 12, 2026, The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. These subsidiaries will continue to pursue the same investment strategies.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures by institutional investors holding more than 5% of a company's stock, affirming their passive investment intent. The Vanguard Group's continued significant stake in Emergent BioSolutions Inc. reflects its ongoing presence as a major passive investor in the biotechnology and pharmaceutical sector, consistent with its broad market index strategies.

Stakeholder Impact

• Shareholders of Emergent BioSolutions Inc. are informed of The Vanguard Group's continued significant ownership stake.
• The internal realignment at Vanguard primarily impacts Vanguard's internal reporting structure and its subsidiaries.

Next Steps

• Certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.

Key Dates

Keywords

Emergent BioSolutions, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, EBS